Product logins

Find logins to all Clarivate products below.


Biomarker-Driven Prescribing in Oncology: Physician and Payer Insights on Evolving Trends in Key Indications | Physician & Payer Forum | US | 2014

Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as breast cancer, colorectal cancer, and malignant melanoma, and is affecting uptake of key brands. In addition, multiple emerging therapies in the oncology pipeline, such as Novartis’s Zykadia (ceritinib) and Amgen’s rilotumumab, hope to benefit from biomarker-driven prescribing.

Predictive biomarkers give oncologists more confidence that a patient will respond to a therapy. Biomarker testing also means that payers do not have to reimburse therapies that will not work in biomarker-negative patients, allowing funds to be allocated more efficiently. However, problems can arise in obtaining sufficient high-quality tissue from a biopsy in order to perform biomarker testing, and delays in receiving results of biomarker tests can adversely affect prescribing of biomarker-driven therapies. Furthermore, how biomarker tests are reimbursed will in turn impact uptake of biomarker-driven therapies.

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…